Rafael (RFL) Stock Price, News & Analysis

Company Overview

Rafael Holdings, Inc. is a diversified holding company focused primarily on commercial real estate and life sciences. The company’s real estate activities include ownership and management of commercial properties, with a focus on properties in the New York metropolitan area and other strategic locations.

Through its life sciences investments and subsidiaries, Rafael Holdings has supported the development of oncology treatments and other pharmaceutical technologies. Its best-known biotechnology subsidiary, Rafael Pharmaceuticals, developed investigational cancer therapies, including devimistat, a treatment designed to target cancer-cell metabolism. These programs have been evaluated in clinical studies, although investigational products remain subject to regulatory approval and may not become commercially available.

Rafael Holdings was established following the separation of certain assets from IDT Corporation. The company is associated with entrepreneur Howard S. Jonas, who has played a significant leadership role in its development. Its operations and investments span commercial real estate and biotechnology, with activities primarily connected to the United States.

Key Stats

• Today's Range: $2.01 to $2.15
• 50-Day Range: $1.83 to $2.60
• 52-Week Range: $1.12 to $3.96
• Volume: 63,764 shs
• Average Volume: 113,523 shs
• Market Capitalization: $108.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Rafael Stock Analysis - MarketRank™

Rafael scored higher than 4% of companies evaluated by MarketBeat, and ranked 894th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Rafael has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Rafael has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Rafael is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rafael is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rafael has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.26% of the float of Rafael has been sold short.

Short Interest Ratio / Days to Cover

Rafael has a short interest ratio ("days to cover") of 6.35.

Change versus previous month

Short interest in Rafael has recently increased by 97.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rafael does not currently pay a dividend.

Dividend Growth

Rafael does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Rafael has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Rafael this week, compared to 0 articles on an average week.

MarketBeat Follows

2 people have added Rafael to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rafael insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.90% of the stock of Rafael is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.30% of the stock of Rafael is held by institutions.

Company Calendar

• Last Earnings: 10/29/2025
• Today: 9/17/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 7/31/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:RFL
• CIK: 1713863
• Web: www.rafaelholdings.com
• Phone: (212) 658-1450
• Fax: N/A
• Employees: 23
• Year Founded: 2000

Profitability

• EPS (Trailing Twelve Months): ($0.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.52 million
• Net Margins: -3,321.74%
• Pretax Margin: -3,182.25%
• Return on Equity: -41.27%
• Return on Assets: -35.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.16
• Quick Ratio: 3.14

Sales & Book Value

• Annual Sales: $920 thousand
• Price / Sales: 117.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.91 per share
• Price / Book: 1.09

Miscellaneous

• Outstanding Shares: 52,000,000
• Free Float: 34,892,000
• Market Cap: $108.37 million
• Optionable: Optionable
• Beta: 0.40